Randomized factorial trial of esomeprazole and aspirin in Barrett’s oesophagus: the Aspirin and Esomeprazole Chemoprevention in Barrett’s metaplasia Trial (AspECT)Tools Jankowski, Janusz A.Z., de Caestecker, John, Love, Sharon B., Reilly, Gavin, Watson, Peter, Sanders, Scott, Ang, Yeng, Morris, Danielle, Bhandari, Pradeep, Attwood, Stephen, Ragunath, Krish, Rameh, Bashir, Fullarton, Grant, Tucker, Art, Penman, Ian, Rodgers, Colin, Neale, James, Brooks, Claire, Wise, Adelyn, Jones, Stephen, Church, Nicholas, Gibbons, Michael, Johnston, David, Vaidya, Kishor, Anderson, Mark, Balata, Sherzad, Davies, Gareth, Dickey, William, Goddard, Andrew, Edwards, Cathryn, Gore, Stephen, Haigh, Chris, Harding, Timothy, Isaacs, Peter, Jackson, Lucina, Lee, Thomas, Lim, Peik Loon, Macdonald, Christopher, Mairs, Philip, McLoughlin, James, Monk, David, Murdock, Andrew, Murray, Iain, Preston, Sean, Pugh, Stirling, Smart, Howard, Soliman, Ashraf, Todd, John, Turner, Graham, Worthington, Joy, Harrison, Rebecca, Barr, Hugh and Moayyedi, Paul (2018) Randomized factorial trial of esomeprazole and aspirin in Barrett’s oesophagus: the Aspirin and Esomeprazole Chemoprevention in Barrett’s metaplasia Trial (AspECT). Lancet Gastroenterology and Hepatology . ISSN 2468-1253 (In Press) Full text not available from this repository.AbstractBackground: Oesophageal adenocarcinoma (OA) is the sixth commonest cause of cancer death worldwide and Barrett’s oesophagus (BO) is the most significant risk factor. We evaluated the efficacy of high-dose esomeprazole proton pump inhibitor acid suppression (PPI) and aspirin in improving outcome for BO patients in the largest such randomized controlled trial.
Actions (Archive Staff Only)
|